{
    "Rank": 1095,
    "Study": {
        "ProtocolSection": {
            "IdentificationModule": {
                "NCTId": "NCT00005822",
                "OrgStudyIdInfo": {
                    "OrgStudyId": "CWRU5199"
                },
                "SecondaryIdInfoList": {
                    "SecondaryIdInfo": [
                        {
                            "SecondaryId": "U01CA062502",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/U01CA062502"
                        },
                        {
                            "SecondaryId": "P30CA043703",
                            "SecondaryIdType": "U.S. NIH Grant/Contract",
                            "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA043703"
                        },
                        {
                            "SecondaryId": "CWRU-5199"
                        },
                        {
                            "SecondaryId": "NCI-T99-0099"
                        }
                    ]
                },
                "Organization": {
                    "OrgFullName": "Case Comprehensive Cancer Center",
                    "OrgClass": "OTHER"
                },
                "BriefTitle": "SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast Cancer",
                "OfficialTitle": "A Phase I Pharmacokinetic, Pharmacodynamic, and Clinical Study of the Combination of the Angiogenesis Inhibitor SU5416 and Doxorubicin in Inflammatory Breast Cancer"
            },
            "StatusModule": {
                "StatusVerifiedDate": "June 2010",
                "OverallStatus": "Completed",
                "ExpandedAccessInfo": {
                    "HasExpandedAccess": "No"
                },
                "StartDateStruct": {
                    "StartDate": "April 2000"
                },
                "PrimaryCompletionDateStruct": {
                    "PrimaryCompletionDate": "December 2002",
                    "PrimaryCompletionDateType": "Actual"
                },
                "CompletionDateStruct": {
                    "CompletionDate": "October 2003",
                    "CompletionDateType": "Actual"
                },
                "StudyFirstSubmitDate": "June 2, 2000",
                "StudyFirstSubmitQCDate": "January 26, 2003",
                "StudyFirstPostDateStruct": {
                    "StudyFirstPostDate": "January 27, 2003",
                    "StudyFirstPostDateType": "Estimate"
                },
                "LastUpdateSubmitDate": "June 10, 2010",
                "LastUpdatePostDateStruct": {
                    "LastUpdatePostDate": "June 11, 2010",
                    "LastUpdatePostDateType": "Estimate"
                }
            },
            "SponsorCollaboratorsModule": {
                "ResponsibleParty": {
                    "ResponsiblePartyOldNameTitle": "Beth A. Overmoyer, MD",
                    "ResponsiblePartyOldOrganization": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center"
                },
                "LeadSponsor": {
                    "LeadSponsorName": "Case Comprehensive Cancer Center",
                    "LeadSponsorClass": "OTHER"
                },
                "CollaboratorList": {
                    "Collaborator": [
                        {
                            "CollaboratorName": "National Cancer Institute (NCI)",
                            "CollaboratorClass": "NIH"
                        }
                    ]
                }
            },
            "OversightModule": {
                "OversightHasDMC": "Yes"
            },
            "DescriptionModule": {
                "BriefSummary": "RATIONALE: SU5416 may stop the growth of breast cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining SU5416 with chemotherapy may kill more cancer cells.\n\nPURPOSE: Phase I trial to study the effectiveness of combining SU5416 and doxorubicin in treating patients who have stage IIIB or stage IV inflammatory breast cancer.",
                "DetailedDescription": "OBJECTIVES:\n\nDetermine the maximum tolerated dose of SU5416 and doxorubicin in patients with stage IIIB or IV inflammatory breast cancer.\nDetermine the overall response, response rate, and progression-free survival rate of patients treated with this regimen.\nDetermine the antiangiogenic effects of this regimen in these patients.\nAssess the relationship of plasma levels of these drugs with safety and efficacy in these patients.\n\nOUTLINE: This is a dose-escalation study.\n\nPatients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1 and SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity. After chemotherapy, all patients undergo a modified radical mastectomy and radiotherapy to the chest wall and regional lymph nodes. Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy.\n\nCohorts of 3-6 patients receive escalating doses of SU5416 and doxorubicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional 3 patients may be treated at that dose level.\n\nPatients are followed every 3 months until disease progression.\n\nPROJECTED ACCRUAL: A total of 15-30 patients will be accrued for this study within 6-9 months."
            },
            "ConditionsModule": {
                "ConditionList": {
                    "Condition": [
                        "Breast Cancer"
                    ]
                },
                "KeywordList": {
                    "Keyword": [
                        "stage IV breast cancer",
                        "recurrent breast cancer",
                        "stage IIIB breast cancer",
                        "inflammatory breast cancer",
                        "male breast cancer"
                    ]
                }
            },
            "DesignModule": {
                "StudyType": "Interventional",
                "PhaseList": {
                    "Phase": [
                        "Phase 1"
                    ]
                },
                "DesignInfo": {
                    "DesignAllocation": "N/A",
                    "DesignInterventionModel": "Single Group Assignment",
                    "DesignPrimaryPurpose": "Treatment",
                    "DesignMaskingInfo": {
                        "DesignMasking": "None (Open Label)"
                    }
                },
                "EnrollmentInfo": {
                    "EnrollmentCount": "21",
                    "EnrollmentType": "Actual"
                }
            },
            "ArmsInterventionsModule": {
                "InterventionList": {
                    "Intervention": [
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "doxorubicin hydrochloride",
                            "InterventionDescription": "Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity."
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "semaxanib",
                            "InterventionDescription": "For all subsequent courses, after course 1 patients SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.",
                            "InterventionOtherNameList": {
                                "InterventionOtherName": [
                                    "SU5416"
                                ]
                            }
                        },
                        {
                            "InterventionType": "Procedure",
                            "InterventionName": "conventional surgery",
                            "InterventionDescription": "Patients undergo a modified radical mastectomy."
                        },
                        {
                            "InterventionType": "Radiation",
                            "InterventionName": "radiation therapy",
                            "InterventionDescription": "Patients undergo radiotherapy to the chest wall and regional lymph nodes."
                        },
                        {
                            "InterventionType": "Drug",
                            "InterventionName": "tamoxifen",
                            "InterventionDescription": "Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy."
                        }
                    ]
                }
            },
            "OutcomesModule": {
                "PrimaryOutcomeList": {
                    "PrimaryOutcome": [
                        {
                            "PrimaryOutcomeMeasure": "Determine the maximum tolerated dose of SU5416 and doxorubicin in patients with stage IIIB or IV inflammatory breast cancer.",
                            "PrimaryOutcomeTimeFrame": "Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity."
                        }
                    ]
                }
            },
            "EligibilityModule": {
                "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically or cytologically confirmed stage IIIB or IV (supraclavicular lymph node involvement or metastasis) inflammatory breast cancer\n\nPrimary or secondary\nNo brain metastases or primary brain tumors\n\nHormone receptor status:\n\nNot specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n18 and over\n\nSex:\n\nMale or female\n\nMenopausal status:\n\nNot specified\n\nPerformance status:\n\nECOG 0-2\n\nLife expectancy:\n\nAt least 12 weeks\n\nHematopoietic:\n\nWBC at least 3,500/mm^3\nGranulocyte count at least 1,500/mm^3\nPlatelet count at least 100,000/mm^3\nHemoglobin greater than 9.0 g/dL\n\nHepatic:\n\nBilirubin normal\nAST and ALT less than 2 times upper limit of normal\nPT and PTT normal OR\nINR less than 1.1\n\nRenal:\n\nCreatinine less than 1.5 mg/dL OR\nCreatinine clearance greater than 60 mL/min\n\nCardiovascular:\n\nLVEF at least 50% by MUGA\nNo New York Heart Association class III or IV heart disease\nNo uncompensated coronary artery disease\nNo myocardial infarction or unstable angina within the past 6 months\nNo deep venous or arterial thrombosis within the past 3 months\n\nPulmonary:\n\nNo history of pulmonary embolism within the past 3 months\n\nOther:\n\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception\nNo history of diabetes mellitus with severe peripheral vascular disease\nNo other prior or concurrent malignancies within the past 10 years except inactive nonmelanomatous skin cancer or carcinoma in situ of the cervix\nNo other uncontrolled illnesses\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\nNo concurrent epoetin alfa or filgrastim (G-CSF)\n\nChemotherapy:\n\nNo more than 2 prior chemotherapy regimens allowed\nNo prior doxorubicin or other anthracycline\n\nEndocrine therapy:\n\nNot specified\n\nRadiotherapy:\n\nPrior radiotherapy allowed\n\nSurgery:\n\nNot specified",
                "HealthyVolunteers": "No",
                "Gender": "All",
                "MinimumAge": "18 Years",
                "StdAgeList": {
                    "StdAge": [
                        "Adult",
                        "Older Adult"
                    ]
                }
            },
            "ContactsLocationsModule": {
                "OverallOfficialList": {
                    "OverallOfficial": [
                        {
                            "OverallOfficialName": "Beth A. Overmoyer, MD, FACP",
                            "OverallOfficialAffiliation": "Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center",
                            "OverallOfficialRole": "Study Chair"
                        }
                    ]
                },
                "LocationList": {
                    "Location": [
                        {
                            "LocationFacility": "Ireland Cancer Center at University Hospitals Case Medical Center",
                            "LocationCity": "Cleveland",
                            "LocationState": "Ohio",
                            "LocationZip": "44106-5065",
                            "LocationCountry": "United States"
                        }
                    ]
                }
            }
        },
        "DerivedSection": {
            "MiscInfoModule": {
                "VersionHolder": "September 08, 2023"
            },
            "ConditionBrowseModule": {
                "ConditionMeshList": {
                    "ConditionMesh": [
                        {
                            "ConditionMeshId": "D000001943",
                            "ConditionMeshTerm": "Breast Neoplasms"
                        },
                        {
                            "ConditionMeshId": "D000058922",
                            "ConditionMeshTerm": "Inflammatory Breast Neoplasms"
                        }
                    ]
                },
                "ConditionAncestorList": {
                    "ConditionAncestor": [
                        {
                            "ConditionAncestorId": "D000009371",
                            "ConditionAncestorTerm": "Neoplasms by Site"
                        },
                        {
                            "ConditionAncestorId": "D000009369",
                            "ConditionAncestorTerm": "Neoplasms"
                        },
                        {
                            "ConditionAncestorId": "D000001941",
                            "ConditionAncestorTerm": "Breast Diseases"
                        },
                        {
                            "ConditionAncestorId": "D000012871",
                            "ConditionAncestorTerm": "Skin Diseases"
                        }
                    ]
                },
                "ConditionBrowseLeafList": {
                    "ConditionBrowseLeaf": [
                        {
                            "ConditionBrowseLeafId": "M4910",
                            "ConditionBrowseLeafName": "Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M14540",
                            "ConditionBrowseLeafName": "Recurrence",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M28985",
                            "ConditionBrowseLeafName": "Inflammatory Breast Neoplasms",
                            "ConditionBrowseLeafAsFound": "Inflammatory Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "M20355",
                            "ConditionBrowseLeafName": "Breast Neoplasms, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M4908",
                            "ConditionBrowseLeafName": "Breast Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "M15364",
                            "ConditionBrowseLeafName": "Skin Diseases",
                            "ConditionBrowseLeafRelevance": "low"
                        },
                        {
                            "ConditionBrowseLeafId": "T3067",
                            "ConditionBrowseLeafName": "Inflammatory Breast Cancer",
                            "ConditionBrowseLeafAsFound": "Inflammatory Breast Cancer",
                            "ConditionBrowseLeafRelevance": "high"
                        },
                        {
                            "ConditionBrowseLeafId": "T861",
                            "ConditionBrowseLeafName": "Breast Cancer, Male",
                            "ConditionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "ConditionBrowseBranchList": {
                    "ConditionBrowseBranch": [
                        {
                            "ConditionBrowseBranchAbbrev": "BC04",
                            "ConditionBrowseBranchName": "Neoplasms"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC17",
                            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "All",
                            "ConditionBrowseBranchName": "All Conditions"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "BC23",
                            "ConditionBrowseBranchName": "Symptoms and General Pathology"
                        },
                        {
                            "ConditionBrowseBranchAbbrev": "Rare",
                            "ConditionBrowseBranchName": "Rare Diseases"
                        }
                    ]
                }
            },
            "InterventionBrowseModule": {
                "InterventionMeshList": {
                    "InterventionMesh": [
                        {
                            "InterventionMeshId": "D000013629",
                            "InterventionMeshTerm": "Tamoxifen"
                        },
                        {
                            "InterventionMeshId": "D000004317",
                            "InterventionMeshTerm": "Doxorubicin"
                        },
                        {
                            "InterventionMeshId": "C000506643",
                            "InterventionMeshTerm": "Liposomal doxorubicin"
                        }
                    ]
                },
                "InterventionAncestorList": {
                    "InterventionAncestor": [
                        {
                            "InterventionAncestorId": "D000000903",
                            "InterventionAncestorTerm": "Antibiotics, Antineoplastic"
                        },
                        {
                            "InterventionAncestorId": "D000000970",
                            "InterventionAncestorTerm": "Antineoplastic Agents"
                        },
                        {
                            "InterventionAncestorId": "D000059005",
                            "InterventionAncestorTerm": "Topoisomerase II Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000059003",
                            "InterventionAncestorTerm": "Topoisomerase Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000004791",
                            "InterventionAncestorTerm": "Enzyme Inhibitors"
                        },
                        {
                            "InterventionAncestorId": "D000045504",
                            "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                        },
                        {
                            "InterventionAncestorId": "D000004965",
                            "InterventionAncestorTerm": "Estrogen Antagonists"
                        },
                        {
                            "InterventionAncestorId": "D000006727",
                            "InterventionAncestorTerm": "Hormone Antagonists"
                        },
                        {
                            "InterventionAncestorId": "D000006730",
                            "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                        },
                        {
                            "InterventionAncestorId": "D000045505",
                            "InterventionAncestorTerm": "Physiological Effects of Drugs"
                        },
                        {
                            "InterventionAncestorId": "D000018931",
                            "InterventionAncestorTerm": "Antineoplastic Agents, Hormonal"
                        },
                        {
                            "InterventionAncestorId": "D000020845",
                            "InterventionAncestorTerm": "Selective Estrogen Receptor Modulators"
                        },
                        {
                            "InterventionAncestorId": "D000020847",
                            "InterventionAncestorTerm": "Estrogen Receptor Modulators"
                        },
                        {
                            "InterventionAncestorId": "D000050071",
                            "InterventionAncestorTerm": "Bone Density Conservation Agents"
                        }
                    ]
                },
                "InterventionBrowseLeafList": {
                    "InterventionBrowseLeaf": [
                        {
                            "InterventionBrowseLeafId": "M7182",
                            "InterventionBrowseLeafName": "Doxorubicin",
                            "InterventionBrowseLeafAsFound": "Included",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M227283",
                            "InterventionBrowseLeafName": "Liposomal doxorubicin",
                            "InterventionBrowseLeafAsFound": "Included",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M13935",
                            "InterventionBrowseLeafName": "Progesterone",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M16093",
                            "InterventionBrowseLeafName": "Tamoxifen",
                            "InterventionBrowseLeafAsFound": "Minimum",
                            "InterventionBrowseLeafRelevance": "high"
                        },
                        {
                            "InterventionBrowseLeafId": "M7806",
                            "InterventionBrowseLeafName": "Estrogens",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M22008",
                            "InterventionBrowseLeafName": "Angiogenesis Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M345553",
                            "InterventionBrowseLeafName": "Semaxinib",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3912",
                            "InterventionBrowseLeafName": "Anti-Bacterial Agents",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M3914",
                            "InterventionBrowseLeafName": "Antibiotics, Antitubercular",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7641",
                            "InterventionBrowseLeafName": "Enzyme Inhibitors",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M7804",
                            "InterventionBrowseLeafName": "Estrogen Antagonists",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M30173",
                            "InterventionBrowseLeafName": "Estrogen Receptor Antagonists",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9479",
                            "InterventionBrowseLeafName": "Hormones",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M9478",
                            "InterventionBrowseLeafName": "Hormone Antagonists",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M20656",
                            "InterventionBrowseLeafName": "Antineoplastic Agents, Hormonal",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M22287",
                            "InterventionBrowseLeafName": "Selective Estrogen Receptor Modulators",
                            "InterventionBrowseLeafRelevance": "low"
                        },
                        {
                            "InterventionBrowseLeafId": "M22289",
                            "InterventionBrowseLeafName": "Estrogen Receptor Modulators",
                            "InterventionBrowseLeafRelevance": "low"
                        }
                    ]
                },
                "InterventionBrowseBranchList": {
                    "InterventionBrowseBranch": [
                        {
                            "InterventionBrowseBranchAbbrev": "ANeo",
                            "InterventionBrowseBranchName": "Antineoplastic Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "All",
                            "InterventionBrowseBranchName": "All Drugs and Chemicals"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "BDCA",
                            "InterventionBrowseBranchName": "Bone Density Conservation Agents"
                        },
                        {
                            "InterventionBrowseBranchAbbrev": "Infe",
                            "InterventionBrowseBranchName": "Anti-Infective Agents"
                        }
                    ]
                }
            }
        }
    }
}